337 related articles for article (PubMed ID: 31836136)
1. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
Li X; Wang H; Li T; Wang L; Wu X; Liu J; Xu Y; Wei W
Curr Probl Cancer; 2020 Apr; 44(2):100516. PubMed ID: 31836136
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Ye Q; Ling S; Zheng S; Xu X
Mol Cancer; 2019 Jul; 18(1):114. PubMed ID: 31269959
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives.
Bardol T; Pageaux GP; Assenat E; Alix-Panabières C
Clin Chem; 2024 Jan; 70(1):33-48. PubMed ID: 37962158
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma.
Temraz S; Nasr R; Mukherji D; Kreidieh F; Shamseddine A
Expert Rev Mol Diagn; 2022 May; 22(5):507-518. PubMed ID: 35758097
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
Lyu X; Tsui YM; Ho DW; Ng IO
Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
[TBL] [Abstract][Full Text] [Related]
7. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma.
Trevisan França de Lima L; Broszczak D; Zhang X; Bridle K; Crawford D; Punyadeera C
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188451. PubMed ID: 33065194
[TBL] [Abstract][Full Text] [Related]
8. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
Weng J; Atyah M; Zhou C; Ren N
Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
Li J; Han X; Yu X; Xu Z; Yang G; Liu B; Xiu P
J Exp Clin Cancer Res; 2018 Sep; 37(1):213. PubMed ID: 30176913
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring.
Shaik MR; Sagar PR; Shaik NA; Randhawa N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445822
[TBL] [Abstract][Full Text] [Related]
11. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Circulating Tumor Cells for Predicting of Hepatocellular Carcinoma in Hepatitis C Virus-High Risk Patients: Role of Liquid Biopsy.
El-Mezayen HA; El -Kassas M; El-Taweel FM; Metwally FM; Ghonaim NA; Zahran RF
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2541-2549. PubMed ID: 35901363
[TBL] [Abstract][Full Text] [Related]
13. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
14. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.
Pandyarajan V; Govalan R; Yang JD
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418899
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma.
Sun YF; Guo W; Xu Y; Shi YH; Gong ZJ; Ji Y; Du M; Zhang X; Hu B; Huang A; Chen GG; Lai PBS; Cao Y; Qiu SJ; Zhou J; Yang XR; Fan J
Clin Cancer Res; 2018 Feb; 24(3):547-559. PubMed ID: 29070526
[No Abstract] [Full Text] [Related]
17. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA.
Lin D; Luo R; Ye Z; Wei Q; Bae H; Juon HS; Hann HW; Posey J; Wang C
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102161. PubMed ID: 37307947
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
